ImClone suffers setback from drug rejection
An experimental cancer drug that was expected to boost the fortunes of biotechnology company ImClone Systems Inc. and its partner Bristol-Myers Squibb Co. suffered a setback when the U.S Food and
An experimental cancer drug that was expected to boost the fortunes of biotechnology company ImClone Systems Inc. and its partner Bristol-Myers Squibb Co. suffered a setback when the U.S Food and